The Government Accountability Office (GAO) released its study on TriCare coverage and reimbursement of compounded prescriptions, today. The GAO recommendation? Though compounded drugs represent a small share of TRICARE’s overall drug costs, its costs for these drugs have risen significantly in recent years. Moreover, because most of these drugs contain bulk drug substances generally not approved by FDA, TRICARE’s practice of paying for them is inconsistent with its regulations and results in added costs for the program.
TRICARE’s Payment Practices Should Be More Consistent with Regulations
GAO-15-64: Published: Oct 2, 2014. Publicly Released: Oct 2, 2014.
Click here to read a one-page GAO Summary.
Click here to read the full GAO Report.